Alan M Fogelman Selected Research

Apolipoprotein A-I (Apolipoprotein A1)

1/2022	ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV.
1/2022	Oxidized phospholipids cause changes in jejunum mucus that induce dysbiosis and systemic inflammation.
1/2021	Apolipoprotein mimetics in cancer.
1/2021	Apolipoprotein A-I mimetics attenuate macrophage activation in chronic treated HIV.
1/2020	Oral 15-Hydroxyeicosatetraenoic Acid Induces Pulmonary Hypertension in Mice by Triggering T Cell-Dependent Endothelial Cell Apoptosis.
11/2019	Apolipoprotein A-I mimetics mitigate intestinal inflammation in COX2-dependent inflammatory bowel disease model.
10/2019	The role of the small intestine in modulating metabolism and inflammation in atherosclerosis and cancer.
1/2018	Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung Cancer.
11/2016	ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer.
2/2016	Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alan M Fogelman Research Topics

Disease

64	Atherosclerosis 10/2019 - 01/2002
40	Inflammation (Inflammations) 01/2022 - 04/2002
11	Neoplasms (Cancer) 01/2021 - 11/2010
10	Coronary Disease (Coronary Heart Disease) 11/2017 - 08/2002
8	Dyslipidemias (Dyslipidemia) 10/2019 - 07/2007
7	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 10/2003
5	Coronary Artery Disease (Coronary Atherosclerosis) 01/2014 - 08/2002
4	Atherosclerotic Plaque (Atheroma) 12/2020 - 12/2004
4	Ovarian Neoplasms (Ovarian Cancer) 12/2018 - 11/2010
4	Human Influenza (Influenza) 11/2008 - 08/2002
4	Infections 08/2008 - 08/2002
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022 - 01/2017
3	HIV Infections (HIV Infection) 01/2022 - 02/2011
3	Chronic Kidney Failure (Chronic Renal Failure) 06/2011 - 08/2009
3	Rheumatoid Arthritis 10/2009 - 08/2006
3	Cognitive Dysfunction 11/2008 - 10/2006
2	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2018
2	Pulmonary Hypertension 01/2020 - 08/2014
2	Carcinogenesis 10/2019 - 01/2018
2	Obesity 01/2019 - 04/2007
2	Reperfusion Injury 01/2019 - 12/2013
2	Hypercholesterolemia 01/2017 - 01/2014
2	Adenocarcinoma 11/2016 - 11/2010
2	Vascular Diseases (Vascular Disease) 12/2015 - 08/2014
2	Pulmonary Arterial Hypertension 12/2015 - 08/2014
2	Hypoxia (Hypoxemia) 08/2014 - 08/2012
2	Acute-Phase Reaction 04/2011 - 08/2006
2	Proteinuria 11/2010 - 01/2010
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2010 - 08/2006
2	Arthritis (Polyarthritis) 01/2009 - 05/2008
1	Dysbiosis 01/2022
1	Melanoma (Melanoma, Malignant) 12/2020
1	Glucose Intolerance 01/2019
1	Infarction (Infarctions) 01/2019
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2019
1	Breast Neoplasms (Breast Cancer) 11/2016

Drug/Important Bio-Agent (IBA)

46	Peptides (Polypeptides)IBA 01/2022 - 01/2002
42	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2022 - 01/2002
28	LipidsIBA 01/2020 - 08/2002
20	HDL LipoproteinsIBA 01/2016 - 10/2003
19	ApolipoproteinsIBA 01/2021 - 10/2003
18	CholesterolIBA 10/2019 - 01/2002
13	Phospholipids (Phosphatides)FDA LinkGeneric 01/2022 - 08/2002
12	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2005
12	HDL CholesterolIBA 11/2016 - 08/2002
11	AntioxidantsIBA 01/2022 - 10/2004
11	Apolipoproteins E (ApoE)IBA 01/2016 - 09/2004
10	Lipoproteins (Lipoprotein)IBA 01/2021 - 06/2004
10	LDL Receptors (LDL Receptor)IBA 10/2019 - 08/2002
10	Aryldialkylphosphatase (Paraoxonase)IBA 01/2019 - 08/2002
10	oxidized low density lipoproteinIBA 11/2016 - 08/2002
8	lysophosphatidic acidIBA 04/2015 - 11/2010
5	EnzymesIBA 10/2019 - 11/2005
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2017 - 12/2003
4	Insulin (Novolin)FDA Link 01/2019 - 12/2010
4	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 06/2004
4	Interleukin-6 (Interleukin 6)IBA 10/2018 - 08/2002
4	Biomarkers (Surrogate Marker)IBA 06/2012 - 08/2006
4	LDL Lipoproteins (beta Lipoproteins)IBA 06/2011 - 06/2004
4	Amino Acids FDA Link 01/2009 - 01/2002
3	oxidized- L- alpha- 1- palmitoyl- 2- arachidonoyl- sn- glycero- 3- phosphorylcholineIBA 11/2015 - 04/2002
3	Triglycerides (Triacylglycerol)IBA 08/2015 - 01/2008
3	apolipoprotein A-I mimetic peptide 4FIBA 08/2014 - 01/2009
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2022 - 11/2019
2	lipopolysaccharide-binding proteinIBA 01/2021 - 10/2018
2	EndotoxinsIBA 01/2021 - 11/2019
2	AcidsIBA 01/2020 - 08/2014
2	Serum Amyloid A Protein (Serum Amyloid A)IBA 10/2018 - 04/2013
2	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 01/2017 - 04/2015
2	Particulate MatterIBA 01/2017 - 06/2013
2	HemopexinIBA 01/2016 - 07/2009
2	Oxidants (Oxidizing Agents)IBA 12/2015 - 08/2010
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2012 - 04/2011
2	Liver X ReceptorsIBA 06/2012 - 10/2003
2	Arachidonic Acid (Vitamin F)IBA 12/2010 - 06/2004
2	Fatty Acids (Saturated Fatty Acids)IBA 12/2010 - 08/2008
2	Pravastatin (Pravachol)FDA LinkGeneric 01/2010 - 05/2008
2	ChemokinesIBA 01/2010 - 05/2008
2	CytokinesIBA 05/2008 - 11/2004
2	LDL CholesterolIBA 09/2003 - 08/2002
1	Pharmaceutical PreparationsIBA 01/2021
1	Lipopolysaccharide ReceptorsIBA 01/2021
1	15-hydroxy-5,8,11,13-eicosatetraenoic acidIBA 01/2020
1	CholatesIBA 11/2019
1	Interleukin-10 (Interleukin 10)IBA 11/2019
1	Piroxicam (Feldene)FDA LinkGeneric 11/2019
1	lipoxin A4IBA 11/2019
1	IntegrinsIBA 10/2019
1	stearoyl-coenzyme A (stearoyl-CoA)IBA 10/2019
1	CalciumIBA 01/2019
1	Insulin-Like Growth Factor I (IGF-1)IBA 12/2018
1	Toll-Like Receptor 4IBA 10/2018
1	LysophospholipidsIBA 01/2017
1	Cholestanol (Coprostanol)IBA 01/2017
1	Ezetimibe (Zetia)FDA Link 01/2017
1	Tumor Viral Antigens (Large T Antigen)IBA 11/2016
1	Chymases (Chymase)IBA 02/2016

Therapy/Procedure

13	Therapeutics 01/2021 - 01/2005
3	Oral Administration 08/2006 - 01/2002
2	Art Therapy 01/2022 - 01/2021